메뉴 건너뛰기




Volumn 159, Issue 1, 2016, Pages 151-162

Treatment of early-stage human epidermal growth factor 2-positive cancers among medicare enrollees: age and race strongly associated with non-use of trastuzumab

Author keywords

Breast cancer; HER2 positive; SEER medicare; Trastuzumab

Indexed keywords

TRASTUZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

EID: 84982854140     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-016-3927-4     Document Type: Article
Times cited : (18)

References (37)
  • 1
    • 0034680102 scopus 로고    scopus 로고
    • Molecular portraits of human breast tumours
    • COI: 1:CAS:528:DC%2BD3cXmt1CnsLw%3D, PID: 10963602
    • Perou CM, Sorlie T, Eisen MB et al (2000) Molecular portraits of human breast tumours. Nature 406:747–752
    • (2000) Nature , vol.406 , pp. 747-752
    • Perou, C.M.1    Sorlie, T.2    Eisen, M.B.3
  • 2
    • 37049183697 scopus 로고
    • Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene
    • COI: 1:CAS:528:DyaL2sXhtVSht7s%3D, PID: 3798106
    • Slamon DJ, Clark GM, Wong SG et al (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177–182
    • (1987) Science , vol.235 , pp. 177-182
    • Slamon, D.J.1    Clark, G.M.2    Wong, S.G.3
  • 3
    • 0024337144 scopus 로고
    • Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
    • COI: 1:STN:280:DyaL1M3kt1Wntg%3D%3D, PID: 2470152
    • Slamon DJ, Godolphin W, Jones LA et al (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707–712
    • (1989) Science , vol.244 , pp. 707-712
    • Slamon, D.J.1    Godolphin, W.2    Jones, L.A.3
  • 4
    • 26844503270 scopus 로고    scopus 로고
    • Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
    • COI: 1:CAS:528:DC%2BD2MXhtFansr3L, PID: 16236737
    • Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659–1672
    • (2005) N Engl J Med , vol.353 , pp. 1659-1672
    • Piccart-Gebhart, M.J.1    Procter, M.2    Leyland-Jones, B.3
  • 5
    • 26844536978 scopus 로고    scopus 로고
    • Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
    • COI: 1:CAS:528:DC%2BD2MXhtFansr3F, PID: 16236738
    • Romond EH, Perez EA, Bryant J et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673–1684
    • (2005) N Engl J Med , vol.353 , pp. 1673-1684
    • Romond, E.H.1    Perez, E.A.2    Bryant, J.3
  • 6
    • 80053539103 scopus 로고    scopus 로고
    • Adjuvant trastuzumab in HER2-positive breast cancer
    • COI: 1:CAS:528:DC%2BC3MXht12mtLvN, PID: 21991949
    • Slamon D, Eiermann W, Robert N et al (2011) Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365:1273–1283
    • (2011) N Engl J Med , vol.365 , pp. 1273-1283
    • Slamon, D.1    Eiermann, W.2    Robert, N.3
  • 7
    • 84864042781 scopus 로고    scopus 로고
    • Trastuzumab containing regimens for early breast cancer
    • Moja L, Tagliabue L, Balduzzi S et al (2012) Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev. doi:10.1002/14651858.CD006243.pub2
    • (2012) Cochrane Database Syst Rev
    • Moja, L.1    Tagliabue, L.2    Balduzzi, S.3
  • 8
    • 84984900276 scopus 로고    scopus 로고
    • National Comphreensive Cancer Network (NCCN) guidelines, Breast Cancer, Version 2.2016 (2016) http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed 27 July 2016
    • (2016) Breast Cancer, Version , vol.2 , pp. 2016
  • 9
    • 84905163505 scopus 로고    scopus 로고
    • US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status
    • PID: 24777111
    • Howlader N, Altekruse SF, Li CI et al (2014) US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. doi:10.1093/jnci/dju055
    • (2014) J Natl Cancer Inst
    • Howlader, N.1    Altekruse, S.F.2    Li, C.I.3
  • 10
    • 84873407216 scopus 로고    scopus 로고
    • Use of adjuvant trastuzumab in women with human epidermal growth factor receptor 2 (HER2)-positive breast cancer by race/ethnicity and education within the National Comprehensive Cancer Network
    • COI: 1:CAS:528:DC%2BC3sXitVOhs7o%3D, PID: 23011924
    • Freedman RA, Hughes ME, Ottesen RA et al (2013) Use of adjuvant trastuzumab in women with human epidermal growth factor receptor 2 (HER2)-positive breast cancer by race/ethnicity and education within the National Comprehensive Cancer Network. Cancer 119:839–846
    • (2013) Cancer , vol.119 , pp. 839-846
    • Freedman, R.A.1    Hughes, M.E.2    Ottesen, R.A.3
  • 11
    • 84958240098 scopus 로고    scopus 로고
    • ReCAP: treatment patterns and cost of care associated with initial therapy among patients diagnosed with operable early-stage human epidermal growth factor receptor 2-overexpressed breast cancer in the United States: a real-world retrospective study
    • Byfield SD, Buck PO, Blauer-Peterson C et al (2016) ReCAP: treatment patterns and cost of care associated with initial therapy among patients diagnosed with operable early-stage human epidermal growth factor receptor 2-overexpressed breast cancer in the United States: a real-world retrospective study. J Oncol Pract 12:159–160
    • (2016) J Oncol Pract , vol.12 , pp. 159-160
    • Byfield, S.D.1    Buck, P.O.2    Blauer-Peterson, C.3
  • 12
    • 84901692250 scopus 로고    scopus 로고
    • Patterns of chemotherapy, toxicity, and short-term outcomes for older women receiving adjuvant trastuzumab-based therapy
    • COI: 1:CAS:528:DC%2BC2cXntFOlt7k%3D, PID: 24756187
    • Freedman RA, Vaz-Luis I, Barry WT et al (2014) Patterns of chemotherapy, toxicity, and short-term outcomes for older women receiving adjuvant trastuzumab-based therapy. Breast Cancer Res Treat 145:491–501
    • (2014) Breast Cancer Res Treat , vol.145 , pp. 491-501
    • Freedman, R.A.1    Vaz-Luis, I.2    Barry, W.T.3
  • 13
    • 84899644277 scopus 로고    scopus 로고
    • Duration and toxicity of adjuvant trastuzumab in older patients with early-stage breast cancer: a population-based study
    • COI: 1:CAS:528:DC%2BC2cXosVyisb8%3D, PID: 24516021
    • Vaz-Luis I, Keating NL, Lin NU et al (2014) Duration and toxicity of adjuvant trastuzumab in older patients with early-stage breast cancer: a population-based study. J Clin Oncol 32:927–934
    • (2014) J Clin Oncol , vol.32 , pp. 927-934
    • Vaz-Luis, I.1    Keating, N.L.2    Lin, N.U.3
  • 14
    • 84971664105 scopus 로고    scopus 로고
    • Disparities in use of human epidermal growth hormone receptor 2-targeted therapy for early-stage breast cancer
    • PID: 27069085
    • Reeder-Hayes K, Peacock Hinton S, Meng K et al (2016) Disparities in use of human epidermal growth hormone receptor 2-targeted therapy for early-stage breast cancer. J Clin Oncol 34:2003–2009
    • (2016) J Clin Oncol , vol.34 , pp. 2003-2009
    • Reeder-Hayes, K.1    Peacock Hinton, S.2    Meng, K.3
  • 15
    • 84905860749 scopus 로고    scopus 로고
    • Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study
    • PID: 24888816
    • Vaz-Luis I, Ottesen RA, Hughes ME et al (2014) Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study. J Clin Oncol 32:2142–2150
    • (2014) J Clin Oncol , vol.32 , pp. 2142-2150
    • Vaz-Luis, I.1    Ottesen, R.A.2    Hughes, M.E.3
  • 16
    • 17144465669 scopus 로고    scopus 로고
    • Measuring complications of cancer treatment using the SEER-Medicare data
    • Potosky AL, Warren JL, Riedel ER et al (2002) Measuring complications of cancer treatment using the SEER-Medicare data. Med Care 40:IV62–IV68
    • (2002) Med Care , vol.40 , pp. IV62-IV68
    • Potosky, A.L.1    Warren, J.L.2    Riedel, E.R.3
  • 17
    • 0038478965 scopus 로고    scopus 로고
    • Overview of the SEER-medicare data: content, research applications, and generalizability to the United States elderly population
    • Warren JL, Klabunde CN, Schrag D et al (2002) Overview of the SEER-medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 40:IV3–IV18
    • (2002) Med Care , vol.40 , pp. IV3-IV18
    • Warren, J.L.1    Klabunde, C.N.2    Schrag, D.3
  • 18
    • 20044388527 scopus 로고    scopus 로고
    • Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer
    • COI: 1:CAS:528:DC%2BD2MXitVSnsLY%3D, PID: 15741529
    • Muss HB, Woolf S, Berry D et al (2005) Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA 293:1073–1081
    • (2005) JAMA , vol.293 , pp. 1073-1081
    • Muss, H.B.1    Woolf, S.2    Berry, D.3
  • 19
    • 33745528525 scopus 로고    scopus 로고
    • Use and outcomes of adjuvant chemotherapy in older women with breast cancer
    • PID: 16782915
    • Giordano SH, Duan Z, Kuo YF et al (2006) Use and outcomes of adjuvant chemotherapy in older women with breast cancer. J Clin Oncol 24:2750–2756
    • (2006) J Clin Oncol , vol.24 , pp. 2750-2756
    • Giordano, S.H.1    Duan, Z.2    Kuo, Y.F.3
  • 20
    • 34447252614 scopus 로고    scopus 로고
    • Social and racial differences in selection of breast cancer adjuvant chemotherapy regimens
    • PID: 17577029
    • Griggs JJ, Culakova E, Sorbero ME et al (2007) Social and racial differences in selection of breast cancer adjuvant chemotherapy regimens. J Clin Oncol 25:2522–2527
    • (2007) J Clin Oncol , vol.25 , pp. 2522-2527
    • Griggs, J.J.1    Culakova, E.2    Sorbero, M.E.3
  • 21
    • 84869125207 scopus 로고    scopus 로고
    • Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer
    • COI: 1:CAS:528:DC%2BC3sXosVCltQ%3D%3D, PID: 22987084
    • Romond EH, Jeong JH, Rastogi P et al (2012) Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 30:3792–3799
    • (2012) J Clin Oncol , vol.30 , pp. 3792-3799
    • Romond, E.H.1    Jeong, J.H.2    Rastogi, P.3
  • 22
    • 84905858933 scopus 로고    scopus 로고
    • Trastuzumab-associated cardiac events at 8 years of median follow-up in the herceptin adjuvant trial (BIG 1-01)
    • PID: 24912899
    • de Azambuja E, Procter MJ, van Veldhuisen DJ et al (2014) Trastuzumab-associated cardiac events at 8 years of median follow-up in the herceptin adjuvant trial (BIG 1-01). J Clin Oncol 32:2159–2165
    • (2014) J Clin Oncol , vol.32 , pp. 2159-2165
    • de Azambuja, E.1    Procter, M.J.2    van Veldhuisen, D.J.3
  • 23
    • 84871319147 scopus 로고    scopus 로고
    • Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer
    • COI: 1:CAS:528:DC%2BC38XhvVCrsLfJ, PID: 23158536
    • Chen J, Long JB, Hurria A et al (2012) Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Coll Cardiol 60:2504–2512
    • (2012) J Am Coll Cardiol , vol.60 , pp. 2504-2512
    • Chen, J.1    Long, J.B.2    Hurria, A.3
  • 24
    • 84866060182 scopus 로고    scopus 로고
    • Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study
    • COI: 1:CAS:528:DC%2BC38XhtlCqtr7N, PID: 22949432
    • Bowles EJ, Wellman R, Feigelson HS et al (2012) Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J Natl Cancer Inst 104:1293–1305
    • (2012) J Natl Cancer Inst , vol.104 , pp. 1293-1305
    • Bowles, E.J.1    Wellman, R.2    Feigelson, H.S.3
  • 25
    • 84892845082 scopus 로고    scopus 로고
    • Trastuzumab-related cardiotoxicity among older patients with breast cancer
    • COI: 1:CAS:528:DC%2BC3sXhvFOnu7jK, PID: 24127446
    • Chavez-MacGregor M, Zhang N, Buchholz TA et al (2013) Trastuzumab-related cardiotoxicity among older patients with breast cancer. J Clin Oncol 31:4222–4228
    • (2013) J Clin Oncol , vol.31 , pp. 4222-4228
    • Chavez-MacGregor, M.1    Zhang, N.2    Buchholz, T.A.3
  • 26
    • 84984873301 scopus 로고    scopus 로고
    • Prophylactic beta blockade preserves left ventricular ejection fraction in HER2-overexpressing breast cancer patients receiving trastuzumab: primary results of the MANTICORE randomized controlled trial. In: San Antonio breast cancer symposium
    • Pituskin EN, Mackey JR, Koshman S et al (2015) Prophylactic beta blockade preserves left ventricular ejection fraction in HER2-overexpressing breast cancer patients receiving trastuzumab: primary results of the MANTICORE randomized controlled trial. In: San Antonio breast cancer symposium. San Antonio (abstr S1–05)
    • (2015) San Antonio (abstr S1–05)
    • Pituskin, E.N.1    Mackey, J.R.2    Koshman, S.3
  • 27
    • 84984873309 scopus 로고    scopus 로고
    • Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): primary results of a randomized, 2 × 2 factorial, placebo-controlled, double-blind clinical trial. In: 2015 American Heart Association Scientific Sessions
    • Gulati G, Heck SL, Hoffmann PS (2015) Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): primary results of a randomized, 2 × 2 factorial, placebo-controlled, double-blind clinical trial. In: 2015 American Heart Association Scientific Sessions. Orlando (abstr 478895)
    • (2015) Orlando (abstr 478895)
    • Gulati, G.1    Heck, S.L.2    Hoffmann, P.S.3
  • 30
    • 59949093293 scopus 로고    scopus 로고
    • Trends in racial and age disparities in definitive local therapy of early-stage breast cancer
    • PID: 19103731
    • Freedman RA, He Y, Winer EP, Keating NL (2009) Trends in racial and age disparities in definitive local therapy of early-stage breast cancer. J Clin Oncol 27:713–719
    • (2009) J Clin Oncol , vol.27 , pp. 713-719
    • Freedman, R.A.1    He, Y.2    Winer, E.P.3    Keating, N.L.4
  • 31
    • 39049093871 scopus 로고    scopus 로고
    • Racial disparities in cancer therapy: did the gap narrow between 1992 and 2002?
    • PID: 18181101
    • Gross CP, Smith BD, Wolf E, Andersen M (2008) Racial disparities in cancer therapy: did the gap narrow between 1992 and 2002? Cancer 112:900–908
    • (2008) Cancer , vol.112 , pp. 900-908
    • Gross, C.P.1    Smith, B.D.2    Wolf, E.3    Andersen, M.4
  • 32
    • 33645455347 scopus 로고    scopus 로고
    • Missed opportunities: racial disparities in adjuvant breast cancer treatment
    • PID: 16549830
    • Bickell NA, Wang JJ, Oluwole S et al (2006) Missed opportunities: racial disparities in adjuvant breast cancer treatment. J Clin Oncol 24:1357–1362
    • (2006) J Clin Oncol , vol.24 , pp. 1357-1362
    • Bickell, N.A.1    Wang, J.J.2    Oluwole, S.3
  • 33
    • 84930149789 scopus 로고    scopus 로고
    • Racial differences in outcomes for patients with metastatic breast cancer by disease subtype
    • PID: 26022349
    • Vaz-Luis I, Lin NU, Keating NL et al (2015) Racial differences in outcomes for patients with metastatic breast cancer by disease subtype. Breast Cancer Res Treat 151:697–707
    • (2015) Breast Cancer Res Treat , vol.151 , pp. 697-707
    • Vaz-Luis, I.1    Lin, N.U.2    Keating, N.L.3
  • 34
    • 84876286032 scopus 로고    scopus 로고
    • Identifying specific chemotherapeutic agents in medicare data: a validation study
    • PID: 22080337
    • Lund JL, Sturmer T, Harlan LC et al (2013) Identifying specific chemotherapeutic agents in medicare data: a validation study. Med Care 51:e27–e34
    • (2013) Med Care , vol.51 , pp. e27-e34
    • Lund, J.L.1    Sturmer, T.2    Harlan, L.C.3
  • 35
    • 84920561845 scopus 로고    scopus 로고
    • Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer
    • PID: 25564897
    • Tolaney SM, Barry WT, Dang CT et al (2015) Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med 372:134–141
    • (2015) N Engl J Med , vol.372 , pp. 134-141
    • Tolaney, S.M.1    Barry, W.T.2    Dang, C.T.3
  • 36
    • 0034531923 scopus 로고    scopus 로고
    • Development of a comorbidity index using physician claims data
    • COI: 1:STN:280:DC%2BD3M%2FptlSrtQ%3D%3D, PID: 11146273
    • Klabunde CN, Potosky AL, Legler JM, Warren JL (2000) Development of a comorbidity index using physician claims data. J Clin Epidemiol 53:1258–1267
    • (2000) J Clin Epidemiol , vol.53 , pp. 1258-1267
    • Klabunde, C.N.1    Potosky, A.L.2    Legler, J.M.3    Warren, J.L.4
  • 37
    • 0027940266 scopus 로고
    • Validation of a combined comorbidity index
    • COI: 1:STN:280:DyaK2M3jvFantQ%3D%3D, PID: 7722560
    • Charlson M, Szatrowski TP, Peterson J, Gold J (1994) Validation of a combined comorbidity index. J Clin Epidemiol 47:1245–1251
    • (1994) J Clin Epidemiol , vol.47 , pp. 1245-1251
    • Charlson, M.1    Szatrowski, T.P.2    Peterson, J.3    Gold, J.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.